What Has Been The Evolution of the Non injectable Insulin Market in Recent Years?
The non injectable insulin market has seen considerable growth due to a variety of factors.
• The market for non-injectable insulin has seen a swift expansion in the past few years. Its growth is projected to increase from $1.92 billion in 2024 to $2.16 billion in 2025, indicating a compound annual growth rate (CAGR) of 12.1%.
The substantial growth during the past period results from enhanced patient compliance, the management of needle phobia, betterment in quality of life, simplicity in administration, and consistent control of blood glucose levels.
What Are the Future Growth Projections for the Non injectable Insulin Market?
The non injectable insulin market is expected to maintain its strong growth trajectory in upcoming years.
• The market for non-injectable insulin is anticipated to witness a swift expansion in the forthcoming years, achieving a size of $3.17 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 10.1%.
The predicted growth during the forecast period can be ascribed to the ongoing focus on patient adherence, enduring solutions for needle fear, advancements in quality of life, sustained safety upgrades, and decreasing the risk of infections and injuries. The forecast period is also expected to see significant trends such as technical innovations, the progression of technological solutions, integration of digital health, nanotechnology incorporations, and combined treatments.
What Are The Core Factors Supporting Growth In The Non injectable Insulin Market?
The surge in obesity and diabetes problems is anticipated to stimulate the expansion of the non-injectable insulin market. Obesity is defined by an overabundance of body fat resulting from a discrepancy between energy consumption and expenditure, while diabetes often classified as a set of metabolic disorders, causes elevated blood sugar levels over an extended period. Non-injectable insulin is employed to treat both conditions and presents the potential to enhance disease management, by easing impediments to insulin therapy, offering possible weight management advantages and introducing more user-friendly treatment options. For example, the World Heart Federation, a Switzerland-based NGO, predicted in 2022 that global obesity rates would escalate, with an estimated 2.3 billion people, including children and adults being overweight or obese in 2021, and this figure is expected to rise to 2.7 billion by 2025. Additionally, a report by the UK-based charity, British Diabetic Association in April 2023, revealed that out of the 4.3 million people diagnosed with diabetes in the UK, over 2.4 million are highly susceptible to type 2 diabetes. The registration numbers for the year 2021-22 have observed a surge of 148,951 compared to the prior year. Thus, the growing prevalence of obesity and diabetes is fuelling the development of the non-injectable insulin market.
What Are The Major Segments Within The Global Non injectable Insulin Market?
The non-injectable insulin market covered in this report is segmented –
1) By Type: Synthetic Insulin, Semi Synthetic Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores
Subsegments:
1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin
2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations
Pre-Book The Non injectable Insulin Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Non injectable Insulin Market?
Major players in the non-injectable insulin market are concentrating their efforts on the innovation of drug delivery technologies, such as needle-free oral insulin sprays, in order to enhance the quality of life of individuals who need to manage their diabetes with multiple insulin injections. A needle-free insulin spray offers an uncomplicated and painless method for controlling blood sugar levels, as doses can be administered directly into the mouth. To illustrate, NiedlFree Technologies, an Indian technology firm, launched Ozulin, an oral insulin spray, in November 2023. Designed to be more user-friendly and beneficial for those who struggle with traditional injectable insulin procedures, this spray is particularly aimed at diabetics. Should it gain approval, Ozulin could revolutionise the experience of diabetes patients, providing a pain-free and more practical substitute for insulin injections.
Who Are the Key Players In The Non injectable Insulin Market?
Major companies operating in the non-injectable insulin market report are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Novartis AG
• Sanofi S.A
• Bristol-Myers Squibb Company
• AstraZeneca
• Abbott Laboratories
• GlaxoSmithKline
• Takeda Pharmaceutical
• Eli Lilly and Company
• Boehringer Ingelheim
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Ipsen S.A.
• Cadila Healthcare Limited
• Dr. Reddy's Laboratories Limited
• Cipla Limited
• Lupin Pharmaceuticals
• Glenmark Pharmaceuticals
• Torrent Pharmaceuticals
• Biocon Limited
• Wockhardt Limited
What Is The Most Dominant Region In The Non injectable Insulin Market?
North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
